Results 31 to 40 of about 11,053 (191)

Adverse events after vaccination among HIV-positive persons, 1990-2016. [PDF]

PLoS ONE, 2018
Human immunodeficiency virus (HIV) causes immune dysregulation, potentially affecting response to vaccines in infected persons. We investigated if unexpected adverse events (AEs) or unusual patterns of AEs after vaccination were reported among HIV ...
John R Su, Carmen Ng, Paige W Lewis, Maria V Cano   +3 more
doaj   +1 more source

Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients [PDF]

, 2021
Background Herpes zoster (HZ) infection of hematopoietic stem cell transplant (HSCT) patients is of clinical concern. Vaccination could help restore immunity to varicella zoster virus (VZV); however, temporal changes in immunogenicity ...
Oh, Myoung-don, Kim, Inho, Lee, Min Kyeong, Chun, June Young, Kang, Chang Kyung, Koh, Youngil, Kim, Kichun, Hong, Junshik, Park, Wan Beom, Kim, Nam Joong, Shin, Dong-Yeop, Yoon, Sung-Soo, Choe, Pyoeng Gyun   +12 more
core   +1 more source

Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis

Frontiers in Immunology, 2022
ObjectiveTo investigate the efficacy, effectiveness and safety of recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL) in immunocompetent and immunocompromised subjects.MethodsData sources: PubMed, EMBASE, Cochrane Library, and Web of Science ...
Yue Xia, Xue Zhang, Liuren Zhang, Chuanxi Fu   +3 more
doaj   +1 more source

Membrane‐Permeable Nucleoside T‐1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides

Chemistry – A European Journal, EarlyView.
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier, Duan Li, Leentje Persoons, Graciela Andrei, Robert Snoeck, Dominique Schols, Lieve Naesens, Xiao Jia   +7 more
wiley   +1 more source

Review of Varicella zoster virus : from epidemiology to prevention [PDF]

, 2008
The Varicella zoster virus is a human pathogen which causes Varicella after primary infection and herpes zoster after secondary reactivation. Both disease manifestations can occur at any age; however, Varicella is seen more commonly in children whilst ...
Pace, David
core  

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Herpes zoster vaccination in systemic lupus erythematosus: the current status

Human Vaccines & Immunotherapeutics, 2019
Among the inflammatory rheumatic diseases, SLE is associated with the highest risk of herpes zoster reactivation relative to age. The reported incidence of herpes zoster infection in SLE ranges from 6.4 to 91.4/1000 patient-years, with main risk factors ...
Chi Chiu Mok
doaj   +1 more source

Modelling Impact of Different Varicella Immunisation Strategies Upon Introduction in the Swedish National Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Countries with varicella immunisation programmes have seen major reductions in disease burden. While two‐dose schedules are now universally adopted, dosing ages vary, and some countries initially include catch‐up vaccination of older children to speed impact. This modelling study assessed three two‐dose schedules in the Swedish setting (1)
Gianpaolo Scalia Tomba, Frida Kasteng, Annika Ersson, Sören Andersson, Emma Appelqvist, Marie Nordahl, Kari Johansen   +6 more
wiley   +1 more source

Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Under Swedish law, a vaccination may be included in the National Immunisation Programme (NIP) if it effectively prevents transmission in the population, is cost‐effective and aligns with ethical and humanitarian principles. The Public Health Agency of Sweden (PHAS) evaluated these criteria for introducing varicella vaccination. Methods The
Annika Ersson, Kari Johansen, Sören Andersson   +2 more
wiley   +1 more source

A fresh look at varicella vaccination

Human Vaccines & Immunotherapeutics
The varicella vaccine is a live attenuated varicella zoster virus (VZV), first produced by Michiaki Takahashi (1974). Subsequent development of the fluorescent antibody to VZV membrane antigen test (FAMA), an immune correlate, permitted vaccine efficacy ...
Anne A. Gershon, Michael D. Gershon
doaj   +1 more source